Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Terry Yeung

Otolaryngology Denison, TX Doctor of Osteopathy

NPI 1902123698 CMS profile 358290

5012 S US Highway 75, Suite 230, Denison, TX 75020

Open in the dashboard

General payments

$39,045

119 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Terry Yeung of Denison, TX is reported in the CMS Open Payments database as having received $39,045 across 119 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $851 13
2024 General $110 3
2023 General $2,916 6
2022 General $5,975 24
2021 General $6,576 11
2020 General $3,578 15
2019 General $19,039 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Terry Yeung
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Terry Yeung were reported at $851. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Terry Yeung Otolaryngology median Middle half National median
2019 $19,039 $194 $82–$512 $163
2020 $3,578 $118 $42–$280 $114
2021 $6,576 $167 $63–$444 $132
2022 $5,975 $216 $84–$545 $149
2023 $2,916 $235 $93–$588 $160
2024 $110 $280 $111–$699 $164
2025 $851 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. OptiNose US, Inc. $35,993 75 payments
  2. Stryker Corporation $2,540 28 payments
  3. Abbott Laboratories $184 2 payments
  4. Medtronic, Inc. $96 3 payments
  5. Acclarent, Inc $38 1 payment
  6. Aerin Medical Inc. $33 1 payment
  7. Intersect ENT, Inc. $32 2 payments
  8. Integra LifeSciences Corporation $30 1 payment
  9. Sanofi-Aventis U.S. LLC $22 1 payment
  10. AstraZeneca Pharmaceuticals LP $19 1 payment
  11. Other $59 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $22,455 15 payments
  2. Travel and Lodging $8,196 27 payments
  3. Food and Beverage $3,894 75 payments
  4. Honoraria $2,500 1 payment
  5. Consulting Fee $2,000 1 payment
Products named General payments · program years 2019–2025
  1. Xhance $35,993 75 payments
  2. NA Craniomaxillofacial $1,056 8 payments
  3. NA Craniomaxillofacial $1,056 8 payments
  4. NA Craniomaxillofacial $1,056 8 payments
  5. SCOPIS ENT $907 10 payments
  6. SMARTLOCK $516 4 payments
  7. ENTELLUS - XPRESS ENT DILATION SYSTEM $320 2 payments
  8. XPRESS ENT DILATION SYSTEM $166 4 payments
  9. PROCLAIM $158 1 payment
  10. PROPEL $80 2 payments
  11. Other $501 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

221

Median for Otolaryngology: 297

Drug cost

$4,460

Median for Otolaryngology: $6,314

Branded share of claims

18.1%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 14 $1,373
Ipratropium Bromide Generic 52 $1,312
Ofloxacin Generic 31 $541
Fluticasone Propionate Generic 41 $460
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 26 $321
Cefdinir Generic 18 $265
Methylprednisolone Generic 14 $112
Amoxicillin Generic 25 $76

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$93,527

Medicare's payments for the services billed

Medicare patients

285

Average age 76

Services billed

1,042

160 women, 125 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 39%
COPD 28%
Diabetes 26%
Atrial fibrillation 21%
Depression 21%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record